1. Academic Validation
  2. Effects of Resveratrol, Lovastatin and the mTOR-Inhibitor RAD-001 on Insulin-Induced Genomic Damage In Vitro

Effects of Resveratrol, Lovastatin and the mTOR-Inhibitor RAD-001 on Insulin-Induced Genomic Damage In Vitro

  • Molecules. 2017 Dec 12;22(12):2207. doi: 10.3390/molecules22122207.
Eman Awad 1 Eman M Othman 2 3 Helga Stopper 4
Affiliations

Affiliations

  • 1 Institute of Pharmacology and Toxicology, University of Würzburg, 97078 Würzburg, Germany. [email protected].
  • 2 Institute of Pharmacology and Toxicology, University of Würzburg, 97078 Würzburg, Germany. [email protected].
  • 3 Department of Analytical Chemistry, Faculty of Pharmacy, University of Minia, Minia 11432, Egypt. [email protected].
  • 4 Institute of Pharmacology and Toxicology, University of Würzburg, 97078 Würzburg, Germany. [email protected].
Abstract

Diabetes mellitus (DM) is one of the major current health problems due to lifestyle changes. Before diagnosis and in the early years of disease, Insulin blood levels are elevated. However, Insulin generates low levels of Reactive Oxygen Species (ROS) which are integral to the regulation of a variety of intracellular signaling pathways, but excess levels of Insulin may also lead to DNA oxidation and DNA damage. Three pharmaceutical compounds, resveratrol, lovastatin and the mTOR-inhibitor RAD-001, were investigated due to their known beneficial effects. They showed protective properties against genotoxic damage and significantly reduced ROS after in vitro treatment of cultured cells with Insulin. Therefore, the selected pharmaceuticals may be attractive candidates to be considered for support of DM therapy.

Keywords

genomic damage; insulin; lovastatin; mTOR-inhibitor RAD-001; resveratrol.

Figures
Products